Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): Considerations to optimize study design

British Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2010, Pages 238-244

  Dissanayake, Sanjeeva ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Bioequivalence; Endogenous drugs; Endogenous substances; Exogenous analogues

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS LYNESTRENOL; FOLLITROPIN; GOSERELIN; GROWTH HORMONE; LEVOTHYROXINE; LUTEINIZING HORMONE; POTASSIUM CHLORIDE; RECOMBINANT GROWTH HORMONE; SOMATOSTATIN; THYROTROPIN; THYROXINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL RESEARCH; CONTINUOUS INFUSION; DIET RESTRICTION; DRUG RESEARCH; EMBASE; FOLLITROPIN RELEASE; GROWTH HORMONE RELEASE; HOMEOSTASIS; HUMAN; INFORMATION PROCESSING; MAXIMUM PLASMA CONCENTRATION; MEDICAL DOCUMENTATION; MEDLINE; METHODOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STANDARDIZATION;

FEMALE; HUMANS; MALE; PHARMACOKINETICS; RECEPTORS, CELL SURFACE; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 76649131303     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03585.x     Document Type: Article

References (30)

1. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence (Draft). European Medicines Agency 2008.
2. Schindel F. Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study. Eur J Clin Pharmacol 2000 56 : 685 688.
3. Jacobsen LV, Rolan P, Christensen MS, Knudsen KM, Rasmussen MH. Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution. Growth Horm IGF Res 2000 10 : 93 8.
4. Lugan I, Febbraro S, Lecuelle H, Papasouliotis O, Ho-Nguyena Q, Buraglio M. Bioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormone. Curr Med Res Opin 2005 21 : 121 125.
5. Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2 : 1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin 2008 24 : 1199 1208.
6. Voortman G, van de Post J, Schoemaker RC, van Gerven JM. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe. Hum Reprod 1999 14 : 1698 1702.
7. Dericks-Tan JS, Krög W, Aktories K, Taubert HD. Dose-dependent inhibition by oral contraceptives of the pituitary to release LH and FSH in response to stimulation with LH-RH+. Contraception 1976 14 : 171 181.
8. Mayor GH, Orlando T, Kurtz NM. Limitations of levothyroxine bioequivalence evaluation: analysis of an attempted study. Am J Ther 1995 2 : 417 432.
9. Zimmermann H, Koytchev R, Mayer O, Börner A, Mellinger U, Breitbarth H. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women. Arzneimittelforschung 1998 48 : 941 947.
10. Zdravkovic M, Müller M, Larsen S, Degenkolb J, Pabst G. Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. Int J Clin Pharmacol Ther 2001 39 : 41 6.
11. Gisclon LG, Bowen AJ, O'Reilly TE, Lakewold D, Curtin CR, Larson KL, Palmer SA, Natarajan J, Wong FA. Bioequivalence of a newly developed 17 beta-estradiol tablet vs. an identical reference formulation. Arzneimittelforschung 2000 50 : 910 914.
12. Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE. Multiple-dose pharmacokinetics and bioequivalence of l-carnitine 330-mg tablet vs. 1-g chewable tablet vs. enteral solution in healthy adult male volunteers. J Pharm Sci 1995 84 : 627 633.
13. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Potassium Chloride (Slow-Release Tablets and Capsules) in Vivo Bioequivalence and in Vitro Dissolution Testing. CDER, 2005.
14. Bolton S. Bioequivalence studies for levothyroxine. AAPS J 2005 7 : E47 53.
15. Togawa A, Tanaka T, Nagashima S, Keta H, Kobayashi Y, Nishikawa Y, Yanai M, Tanaka H. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. Br J Clin Pharmacol 2004 58 : 269 276.
16. Walter-Sack I, Clanget C, Ding R, Goeggelmann C, Hinke V, Lang M, Pfeilschifter J, Tayrouz Y, Wegscheider K. Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin Pharmacokinet 2004 43 : 1037 1053.
17. Blakesley VA. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J 2005 7 : E42 6.
18. Behall KM, Scholfield DJ, Hallfrisch JG, Kelsay JL, Reiser S. Seasonal variation in plasma glucose and hormone levels in adult men and women. Am J Clin Nutr 1984 40 : 1352 1356.
19. Levine M, Duffy L, Moore DC, Matej LA. Acclimation of a non-indigenous sub-Artic population: seasonal variation in thyroid function in interior Alaska. Comp Biochem Physiol A Physiol 1995 111 : 209 214.
20. Smals AGH, Ross HA, Kloppenborg PWC. Seasonal variation in serum T3 and T4 levels in man. J Clin Endocrinol Metab 1977 44 : 998 1001.
21. Hegedüs L, Rasmussen N, Knudsen N. Seasonal variation in thyroid size in healthy males. Horm Metab Res 1987 19 : 391 392.
22. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Levothyroxine Sodium Tablets - in Vivo Pharmacokinetic and Bioavailability Studies and in Vitro Dissolution Testing. CDER, 2000.
23. Marzo A. Open questions on bioequivalence: some problems and some solutions. Pharmacol Res 1999 40 : 357 368.
24. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997 277 : 1205 1213.
25. Browne TR, Szabo GK, McEntegart C, Evans JE, Evans BA, Miceli JJ, Quon C, Dougherty CL, Kres J, Davoudi H. Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique. J Clin Pharmacol 1993 33 : 89 94.
26. Benchekroun Y, Ribon B, Falconnet JB, Cherrah Y, Brazier JL. Pharmacokinetic equivalence of 5(ethyl(2H)5)- and unlabelled phenobarbitone. J Clin Pharmacol 1989 29 : 168 173.
27. Pieniaszek HJ Jr., Mayersohn M, Adams MP, Reinhart RJ, Barrett JS. Moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implications. J Clin Pharmacol 1999 39 : 817 825.
28. Theis DL, Lucisano LJ, Halstead GW. Use of stable isotopes for evaluation of drug delivery systems: comparison of ibuprofen release in vivo and in vitro from two biphasic release formulations utilizing different rate-controlling polymers. Pharm Res 1994 11 : 1069 1076.
29. Wolen RL. The application of stable isotopes to studies of drug bioavailability and bioequivalence. J Clin Pharmacol 1986 26 : 419 424.
30. Benchekroun Y, Ribon B, Falconnet JB, Cherrah Y, Brazier JL. Pharmacokinetic equivalence of 5(ethyl(2H)5)- and unlabelled phenobarbitone. J Clin Pharmacol 1989 29 : 168 173.